Fatty Liver Alliance President Mike Betel joined Roger Green to share some results and lessons from his 3rd Annual 30-day Glucose Challenge.
Dr. Kristina Curtis joins Jörn Schattenberg, Louise Campbell and Roger Green to wrap up the Steatotic Think-Thank on SLD, Mike Betel shares lessons from his 30-day Glucose Challenge, and Naim Alkhouri remembers Stephen Harrison while sharing his vision for the future of clinical trials and medical education.
Behavioral Scientist Dr. Kristina Curtis joins Jörn Schattenberg, Louise Campbell and Roger Green to discuss highlights of #SLDThinkTank2025. This conversation focuses on the kinds of feedback and activities most likely to produce successful behavioral change.
This diverse episode includes a discussion of effective behavioral therapies, a look at drug development we did not discuss in prior episodes, and a sober discussion on how to do our best in addressing the important Washington Challenges under Trump and RFK Jr.
Hepatologist and Hepatology Key Opinion Leader Sven Francque joins Jörn Schattenberg, Louise Campbell and Roger Green to discuss the current and future roles of NITs in Drug Development.
Behavioral Scientist Dr. Kristina Curtis joins Jörn Schattenberg, Louise Campbell and Roger Green to discuss highlights of the Global Think Tank on SLD. This conversation focuses on the program’s history and different ideas on behavioral interventions.
This episode includes a discussion on patient management and self-management from the Global Think-Thank on Steatotic Liver Disease plus a segment from April’s Drug Development roundtable focusing on NITs in clinical trials. This week’s Newsmaker is Jose Willemse, President of the Dutch Liver Patients Association.
On the first anniversary of Stephen Harrison’s passing, we take an episode to remember our co-founder and colleague, Stephen Harrison, his contributions to MASH and how his legacy moves forward.
This week’s Newsmaker is Mike Betel, Founder of the Fatty Liver Alliance. He discusses some of the reasons that key MASLD Patient Advocates like himself are getting more visibility at a broader swath of global conferences and the messages he delivers at the conferences he attends.
This concluding segment of the Emerging Trends Conference 2025 Roundtable expresses optimism about the future for Steatotic Liver Disease patients, with a better understanding of how to treat based on viewing steatotic liver disease as a spectrum and an accompanying explosion of the number and diversity of drugs available to treat patients with MASLD, MetALD and ALD.
